title: Minocycline treatment in acute stroke: an open-label, evaluator-blinded study.
abstract: BACKGROUND
  Ischemic animal model studies have shown a neuroprotective effect of minocycline.
  
  
  OBJECTIVE
  To analyze the effect of minocycline treatment in human acute ischemic stroke.
  
  
  METHODS
  We performed an open-label, evaluator-blinded study. Minocycline at a dosage of 200 mg was administered orally for 5 days. The therapeutic window of time was 6 to 24 hours after onset of stroke. Data from NIH Stroke Scale (NIHSS), modified Rankin Scale (mRS), and Barthel Index (BI) were evaluated. The primary objective was to compare changes from baseline to day 90 in NIHSS in the minocycline group vs placebo.
  
  
  RESULTS
  One hundred fifty-two patients were included in the study. Seventy-four patients received minocycline treatment, and 77 received placebo. NIHSS and mRS were significantly lower and BI scores were significantly higher in minocycline-treated patients. This pattern was already apparent on day 7 and day 30 of follow-up. Deaths, myocardial infarctions, recurrent strokes, and hemorrhagic transformations during follow-up did not differ by treatment group.
  
  
  CONCLUSIONS
  Patients with acute stroke had significantly better outcome with minocycline treatment compared with placebo. The findings suggest a potential benefit of minocycline in acute ischemic stroke.
authors.affiliation: Department of Neurology, Edith Wolfson Medical Center, Holon 58100, Israel. y_lampl@hotmail.com
authors.forename: Y
authors.initials: Y
authors.lastname: Lampl
authors.forename: M
authors.initials: M
authors.lastname: Boaz
authors.forename: R
authors.initials: R
authors.lastname: Gilad
authors.forename: M
authors.initials: M
authors.lastname: Lorberboym
authors.forename: R
authors.initials: R
authors.lastname: Dabby
authors.forename: A
authors.initials: A
authors.lastname: Rapoport
authors.forename: M
authors.initials: M
authors.lastname: Anca-Hershkowitz
authors.forename: M
authors.initials: M
authors.lastname: Sadeh
mesh_terms: D000208:Acute Disease / Q000628:therapy; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D002543:Cerebral Hemorrhage / Q000453:epidemiology; D005260:Female; D005911:Gliosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D017628:Microglia / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage* / Q000009:adverse effects; D009026:Mortality; D009203:Myocardial Infarction / Q000453:epidemiology; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects; D010919:Placebos; D055502:Secondary Prevention; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D016037:Single-Blind Method; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D018696:Neuroprotective Agents; D010919:Placebos; D008911:Minocycline